|
|
- Over the last twelve months, the sales forecast has been frequently revised upwards.
- For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
- Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
|
|
|
- The group usually releases earnings worse than estimated.
- The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
|
|
|
|
|
| Sector Bio Therapeutic Drugs |
|
| | 1st jan. | Capitalisation (M$) | Investor Rating |
 |
 | GLYCOMIMETICS, INC. | 2.53% | 184 | - |
| |
|
|
|
| Sales 2020 |
8,40 M
-
-
|
| Net income 2020 |
-50,5 M
-
-
|
| Net Debt 2020 |
-
-
-
|
| P/E ratio 2020 |
-3,49x |
| Yield 2020 |
- |
|
| Capitalization |
184 M
184 M
-
|
| Capi. / Sales 2020 |
21,9x |
| Capi. / Sales 2021 |
- |
| Nbr of Employees |
57 |
| Free-Float |
97,8% |
|
Upcoming event on GLYCOMIMETICS, INC.
Notations Surperformance© Fundamental ratings
|
Overall rating |
| Trading Rating |
|
| Investor Rating |
- |
| Growth (Revenue) |
- |
| Valuation |
- |
| Finances |
- |
| Profitability |
- |
| Earnings quality |
|
| Business Predictability |
|
| P/E ratio |
- |
| Potential |
|
| Yield |
- |
| Consensus |
|
| 7 days EPS revision |
|
| 4 months EPS revision |
|
| 1 year EPS revision |
|
| 4 months Revenue revision |
|
| 1 year Revenue revision |
|
Technical ratings
| Short Term Timing |
|
| Middle Term Timing |
|
| Long Term Timing |
|
| RSI |
|
| Bollinger Spread |
|
| Unusual Volumes |
|
|
Canada
Deutschland
España
France
Italia
Schweiz (DE)
United Kingdom
Report
